You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the QUTENZA (capsaicin) Drug Profile, 2024 PDF Report in the Report Store ~

QUTENZA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Qutenza patents expire, and when can generic versions of Qutenza launch?

Qutenza is a drug marketed by Averitas and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-seven patent family members in twenty-seven countries.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the capsaicin profile page.

DrugPatentWatch® Generic Entry Outlook for Qutenza

Qutenza was eligible for patent challenges on November 16, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 26, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for QUTENZA?
  • What are the global sales for QUTENZA?
  • What is Average Wholesale Price for QUTENZA?
Summary for QUTENZA
International Patents:67
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 150
Clinical Trials: 27
Drug Prices: Drug price information for QUTENZA
What excipients (inactive ingredients) are in QUTENZA?QUTENZA excipients list
DailyMed Link:QUTENZA at DailyMed
Drug patent expirations by year for QUTENZA
Drug Prices for QUTENZA

See drug prices for QUTENZA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for QUTENZA
Generic Entry Date for QUTENZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
PATCH;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for QUTENZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Nantes University HospitalPhase 3
Leiden University Medical CenterN/A
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)N/A

See all QUTENZA clinical trials

US Patents and Regulatory Information for QUTENZA

QUTENZA is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of QUTENZA is ⤷  Subscribe.

This potential generic entry date is based on patent 8,821,920.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 RX Yes Yes 9,226,903 ⤷  Subscribe Y ⤷  Subscribe
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 RX Yes Yes 10,034,841 ⤷  Subscribe Y ⤷  Subscribe
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 RX Yes Yes 8,821,920 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for QUTENZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 10,463,598 ⤷  Subscribe
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 8,889,113 ⤷  Subscribe
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 8,263,059 ⤷  Subscribe
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 10,869,827 ⤷  Subscribe
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 6,239,180 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for QUTENZA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Grunenthal GmbH Qutenza capsaicin EMEA/H/C/000909
Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.
Authorised no no no 2009-05-15
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for QUTENZA

See the table below for patents covering QUTENZA around the world.

Country Patent Number Title Estimated Expiration
Cyprus 1107582 ⤷  Subscribe
Australia 2003289710 THERAPEUTIC PATCH WITH POLYSILOXANE MATRIX COMPRISING CAPSAICIN ⤷  Subscribe
Germany 102004044578 Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht ⤷  Subscribe
Israel 171249 THERAPEUTIC PATCH WITH POLYSILOXANE MATRIX COMPRISING CAPSAICIN ⤷  Subscribe
Brazil PI0318250 Emplastro tópico com matriz de polissiloxano e método para a produção de preparação de um emplastro tópico ⤷  Subscribe
Portugal 2529732 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

QUTENZA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Qutenza

Introduction to Qutenza

Qutenza, a topical, non-systemic, non-opioid pain treatment, has been a significant player in the management of neuropathic pain. Developed by Grünenthal and marketed in the U.S. by its subsidiary Averitas Pharma, Inc., Qutenza has seen substantial growth and expansion in its indications.

Market Size and Growth

The U.S. diabetic neuropathy market, in which Qutenza is a key player, is projected to grow significantly. By 2030, the market is expected to be valued at US$ 2,635.9 million, with a Compound Annual Growth Rate (CAGR) of 5.2% from 2022 to 2030[1].

Key Indications and Approvals

Qutenza has received several critical approvals that have driven its market growth. It was initially approved for treating neuropathic pain associated with postherpetic neuralgia. In 2020, the U.S. Food and Drug Administration (FDA) granted approval for Qutenza to treat neuropathic pain related to diabetic peripheral neuropathy (DPN) of the feet in adults[1][4].

Ongoing Clinical Trials and Future Indications

Averitas Pharma has completed patient recruitment for the Phase III AV001 clinical study, which is assessing Qutenza for the treatment of post-surgical neuropathic pain (PSNP). This trial, if successful, could lead to an expanded indication for Qutenza in the U.S. market, further boosting its market presence[3].

Financial Performance of Grünenthal

Grünenthal, the parent company of Averitas Pharma, has reported strong financial results. In 2023, Grünenthal generated €1.8 billion in revenues, a 10% increase over the prior year. The adjusted EBITDA was €427 million, although it decreased by 3% due to increased investments in Research & Development (R&D), acquisitions, and modernizing production facilities[2][5].

Regional Performance

Grünenthal's strong business performance in the United States, Latin America, and Europe has been a significant factor in its revenue growth. Qutenza, in particular, has seen increased demand in the U.S., where it is indicated for treating postherpetic neuralgia and pain related to diabetic neuropathy of the feet[2].

Competitive Landscape

The neuropathic pain market is competitive, with several major pharmaceutical companies involved. Key players include Novartis AG, Teva Pharmaceuticals, Abbott Laboratories, and Pfizer Inc., among others. However, Qutenza's unique position as a topical, non-systemic, non-opioid treatment sets it apart in the market[4].

Distribution Channels

The distribution of Qutenza is primarily through drug stores and retail pharmacies, which dominated the market in 2022. However, the online pharmacies segment is expected to grow at a higher CAGR due to convenience, improvements in logistics, and ease of payment options[4].

Strategic Investments

Grünenthal has invested significantly in R&D, with over €1 billion spent since 2017. This investment has advanced its R&D pipeline, including the development of Qutenza for new indications. The company has also acquired established brands and grown its presence in key pharmaceutical markets like the United States[2].

CEO Insights

Gabriel Baertschi, CEO and Chairman of the Corporate Executive Board of Grünenthal, highlighted the company's consistent growth strategy and significant investments in R&D. He emphasized that these efforts are aimed at developing innovative solutions for pain management, aligning with the company's vision of a "World Free of Pain"[2].

Patient Impact

Qutenza has advanced the treatment trajectory for patients with neuropathic pain, particularly those with diabetic peripheral neuropathy and postherpetic neuralgia. The treatment provides up to three months of relief from nerve pain with a single local topical application, significantly improving the quality of life for these patients[1][3].

Future Outlook

Given the positive trial data and the potential for expanded indications, Qutenza is poised for continued growth. The submission of a supplemental new drug application (sNDA) in 2026 for the treatment of post-surgical neuropathic pain could further enhance its market position[3].

Key Takeaways

  • Market Growth: The U.S. diabetic neuropathy market, driven by Qutenza, is expected to reach US$ 2,635.9 million by 2030.
  • Approvals and Indications: Qutenza has received FDA approvals for treating neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.
  • Clinical Trials: Ongoing Phase III trials for post-surgical neuropathic pain could lead to expanded indications.
  • Financial Performance: Grünenthal's revenue and adjusted EBITDA have shown significant growth, driven by strong performance in the U.S. and other regions.
  • Strategic Investments: Substantial investments in R&D and acquisitions have positioned Grünenthal for continued growth.

FAQs

Q: What is Qutenza used for?

A: Qutenza is used for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet and postherpetic neuralgia.

Q: Who is the manufacturer of Qutenza?

A: Qutenza is developed by Grünenthal and marketed in the U.S. by its subsidiary Averitas Pharma, Inc.

Q: What is the unique feature of Qutenza?

A: Qutenza is a topical, non-systemic, non-opioid pain treatment that delivers prescription-strength capsaicin directly into the skin.

Q: What are the ongoing clinical trials for Qutenza?

A: Averitas Pharma is conducting a Phase III clinical trial to assess Qutenza for the treatment of post-surgical neuropathic pain.

Q: How has Grünenthal's financial performance been in recent years?

A: Grünenthal has reported record revenues and adjusted EBITDA, with a 10% increase in revenues in 2023 compared to the prior year.

Sources

  1. Coherent Market Insights: U.S. Diabetic Neuropathy Market Size and Forecast to 2030.
  2. Grünenthal: 2023 full-year results.
  3. Clinical Trials Arena: Averitas completes recruitment for trial of QUTENZA to treat PSNP.
  4. Allied Market Research: Neuropathic Pain Market Size, Share, Trends & Demand [2032].
  5. The Pharma Letter: Grünenthal's revenue and earnings growth goes steadily on.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.